ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

BACKGROUND: The role of adjuvant chemotherapy and the value of molecular biomarkers in bladder cancer have not been determined. We aimed to assess the predictive and prognostic values of excision repair cross-complementation 1 (ERCC1) in identifying appropriate patients who may potentially benefit f...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jong-Mu, Sung, Ji-Youn, Park, Se Hoon, Kwon, Ghee Young, Jeong, Byong Chang, Seo, Seong Il, Jeon, Seong Soo, Lee, Hyun Moo, Jo, Jisuk, Choi, Han Yong, Lim, Ho Yeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404914/
https://www.ncbi.nlm.nih.gov/pubmed/22616552
http://dx.doi.org/10.1186/1471-2407-12-187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404914/
https://www.ncbi.nlm.nih.gov/pubmed/22616552
http://dx.doi.org/10.1186/1471-2407-12-187

Ejemplares similares